RA Drug Actemra Successful in Phase III Study
Roche Holdings AG (manufacturer of MabThera® (rituximab) ) announced on July 10 that its new RA drug Actemra has proved successful in a phase III clinical study. The study, called RADIATE (Research on Actemra Determining effIcacy after Anti-Tnf FailurEs) evaluated the effectiveness of the drug in patients whose disease has not responded to at... Read more








